Lotte Bjerre Knudsen lives comfortably in this pleasant, but not showy, £900,000 apartment in central Copenhagen with her ...

Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

Novo Nordisk needs the facilities to help ramp up production of key growth medicines, including semaglutide-based Ozempic for diabetes and Wegovy for obesity, which have seen their growth held ...

The deal is the basis for Novo Nordisk's strategy to create capacities for the production of drugs for diabetes and obesity Ozempic and Wegovy, which, according to analysts, will become the ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the Wegovy formulation for obesity got the green light from the NMPA last month.